Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06088589 · ClinicalTrials.gov registry record · NA

Speech-in-noise Perception in Autism and Fragile X

A NA study of Autism Spectrum Disorder and Fragile X Syndrome, sponsored by Children's Hospital Medical Center, Cincinnati.

Recruiting
Registry status
NA
Development phase
60
Enrollment target
1
Study location

NCT06088589: Recruiting NA study of Autism Spectrum Disorder and Fragile X Syndrome, sponsored by Children's Hospital Medical Center, Cincinnati.

NCT06088589 is a NA study of Autism Spectrum Disorder and Fragile X Syndrome that is actively recruiting participants, run by Children's Hospital Medical Center, Cincinnati. The registered enrollment target is 60 participants, below the 135-participant average among 224 other Autism Spectrum Disorder trials with a reported enrollment target (56% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06088589, a NA study of Autism Spectrum Disorder and Fragile X Syndrome, is actively recruiting participants, sponsored by Children's Hospital Medical Center, Cincinnati.

RECRUITING
Registry status
NA
Development phase
60 participants
Enrollment target
1
Study location

Study Summary

The goal of this study is to identify which brain regions are active during speech-in-noise perception, as well as how those regions interact. The investigators are studying brain activation during speech-in-noise in autism and controls as well as individuals with Fragile X Syndrome. The main question\[s\] it aims to answer are: 1) How does the brain's response to background noise affect a person's ability to understand speech? 2) Can visual cues improve hearing in background noise? Participants will complete the following: * hearing tests * cognitive and behavioral measures * questionnaires about their symptoms * both passive and active hearing tasks while brain activity is recorded with a neuroimaging cap Results will be compared between individuals with autism with and without Fragile X Syndrome as well as individuals without autism.

Primary Outcome

The SRT is the ratio between the loudness of speech and the loudness of background noise in decibels at which a participant can correctly report the digit that is presented at 50% accuracy.

Interventions

  • BEHAVIORAL Mismatch negativity

Study Locations (1)

Ohio

  • Cincinnati Children'S Hospital - Cincinnati

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2023-11-10
Est. Completion 2026-04-30
Phase NA

What NCT06088589 shows while recruiting

NCT06088589 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 135-participant average among 224 other Autism Spectrum Disorder trials with a reported enrollment target (56% lower).

The record links to 2 conditions, with Autism Spectrum Disorder appearing as the primary indexed condition, and to 1 intervention - of which Mismatch negativity is the first listed.

NCT06088589 reports a single indexed study location in Ohio.

Frequently Asked Questions

What is clinical trial NCT06088589 about?

NCT06088589 is a clinical study titled "Speech-in-noise Perception in Autism and Fragile X". The goal of this study is to identify which brain regions are active during speech-in-noise perception, as well as how those regions interact. The investigators are studying brain activation during speech-in-noise in autism and controls as well as individuals with Fragile X Syndrome. The main questi...

What is the current status of trial NCT06088589?

This trial is currently recruiting. It is a NA study. The enrollment target is 60 participants. The study started on 2023-11-10. Estimated completion is 2026-04-30.

What conditions does trial NCT06088589 study?

This clinical trial studies the following conditions: Autism Spectrum Disorder, Fragile X Syndrome.

What interventions are being tested in trial NCT06088589?

The interventions under investigation include: Mismatch negativity (BEHAVIORAL).

Who is sponsoring clinical trial NCT06088589?

This trial is sponsored by Children's Hospital Medical Center, Cincinnati, which has 571 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06088589 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Autism Spectrum Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06088589's enrollment target sits among peer trials

60 118th of 224 higher than 95 of 224 other Autism Spectrum Disorder trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Autism Spectrum Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00576069 · 60 participants

    Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma

  • NCT01297400 · 60 participants · Phase 2

    Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns

  • NCT01734122 · 60 participants

    Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor

  • NCT01804634 · 60 participants · Phase 2

    Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06088589, the US trial registry maintained by the National Library of Medicine. NCT06088589 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.